Rhythm Biosciences Ltd
Rhythm Biosciences Ltd is an Australia-based medical diagnostics company.
The business
Rhythm Biosciences Ltd is an Australia-based medical diagnostics company. The Company is engaged in delivering simple, affordable blood tests for accurate and early detection of cancers. It is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives. The Company’s blood-based technology, a blood test for the detection of Colorectal Cancer (CRC). The ColoSTAT Test-Kit measures five specific protein biomarkers that indicate the likelihood of CRC. The test is an alternative for individuals who are unable or unwilling to participate in current screening programs. It is being updated to meet the IVDR (In vitro diagnostic medical devices regulation) regulatory standards. Its geneType platform personalized predictive test portfolio that uses a combination of genomic and clinical information to predict risk of chronic disease development.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news

Rhythm Biosciences Secures Major Distribution Deal for ColoSTAT with 4Cyte Pathology
Rhythm Biosciences (ASX: RHY) has signed a significant non-exclusive distribution agreement with 4Cyte Pathology for its ColoSTAT test.

Rhythm Biosciences begins ColoSTAT commercial deployment with first physician enrollment
Rhythm Biosciences (ASX: RHY) has initiated the commercial deployment of its ColoSTAT test by enrolling the first physician in its capped Access Program.

Rhythm Biosciences Secures Key Manufacturing Deal for ColoSTAT
Rhythm Biosciences (ASX:RHY) has secured a multi-year manufacturing agreement with Quansys Biosciences for its ColoSTAT reagent kits, ensuring scalab

Rhythm Biosciences’ 2G ColoSTAT colorectal cancer detection kit outperforms predecessor in key testing
Medical diagnostics company Rhythm Biosciences (ASX: RHY) has confirmed that the second version of its ColoSTAT kit for the detection of colorectal cancer has shown significant outperformance on the original. Preliminary testing of 200 patient serum samples using the new multiplex Alpha antibody kit has revealed superior analytical results compared to tests performed on the […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.